A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients.

A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients. Clin Infect Dis. 2020 12 31; 71(11):2777-2786.

View in: PubMed

subject areas

Adult
Antiviral Agents
Double-Blind Method
Hematopoietic Stem Cell Transplantation
Humans
Respiratory Syncytial Virus Infections
Respiratory Tract Infections
Transplant Recipients

authors with profiles

Kathleen Mullane